MY197240A - Method for preparing an extract of hevea latex and composition thereof - Google Patents

Method for preparing an extract of hevea latex and composition thereof

Info

Publication number
MY197240A
MY197240A MYPI2019002474A MYPI2019002474A MY197240A MY 197240 A MY197240 A MY 197240A MY PI2019002474 A MYPI2019002474 A MY PI2019002474A MY PI2019002474 A MYPI2019002474 A MY PI2019002474A MY 197240 A MY197240 A MY 197240A
Authority
MY
Malaysia
Prior art keywords
extract
hevea latex
composition
serum
optionally
Prior art date
Application number
MYPI2019002474A
Inventor
Rapepun Wititsuwannakul
Bhornprom Yoysungnoen
Original Assignee
Thailand Center Of Excellence For Life Sciences
Prince Of Songkla Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thailand Center Of Excellence For Life Sciences, Prince Of Songkla Univ filed Critical Thailand Center Of Excellence For Life Sciences
Publication of MY197240A publication Critical patent/MY197240A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08C—TREATMENT OR CHEMICAL MODIFICATION OF RUBBERS
    • C08C1/00—Treatment of rubber latex
    • C08C1/02—Chemical or physical treatment of rubber latex before or during concentration
    • C08C1/04—Purifying; Deproteinising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Abstract

The present disclosure provides for the method of preparing, from serum of calendered acidified Hevea latex, an extract that is rich in low-molecular weight carbohydrates and having anti-cancer activity. The method comprises the steps of: obtaining the serum released when acidified Hevea latex is calendered; removing debris and micro-organisms from the serum; removing proteins; removing quebrachitol and small polar molecules; optionally dissolving the remaining solid powder in water; further removing proteins by treatment with acid; optionally neutralizing the excess acid; precipitating with solvent; collecting the precipitate; and optionally freeze drying the precipitate. The disclosure also provides a composition comprising the extract of Hevea latex for use in the treatment of cancer growth and/or metastasis and inhibiting tumor cell proliferation in a patient. Furthermore, there are provided a pharmaceutical composition and a functional food composition comprising the disclosed extract of Hevea latex.
MYPI2019002474A 2016-09-02 2016-09-02 Method for preparing an extract of hevea latex and composition thereof MY197240A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TH2016/000075 WO2018044242A1 (en) 2016-09-02 2016-09-02 Method for preparing an extract of hevea latex and composition thereof

Publications (1)

Publication Number Publication Date
MY197240A true MY197240A (en) 2023-06-07

Family

ID=61309153

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019002474A MY197240A (en) 2016-09-02 2016-09-02 Method for preparing an extract of hevea latex and composition thereof

Country Status (4)

Country Link
EP (1) EP3510052A4 (en)
CN (1) CN110023342B (en)
MY (1) MY197240A (en)
WO (1) WO2018044242A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023055307A1 (en) * 2021-09-29 2023-04-06 Master Labs Incorporation Company Limited Process for extracting hevea latex polysaccharides from effluent of the rubber manufacturing industry, polysaccharide extract, composition and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1758616A (en) * 1925-12-02 1930-05-13 Naugatuck Chem Co Method for recovering quebrachitol from rubber latex serum
JPS61293201A (en) * 1985-06-22 1986-12-24 Yokohama Rubber Co Ltd:The Powdered nonrubber component obtained from serum of natural rubber latex and production thereof
JPH0291035A (en) * 1988-07-06 1990-03-30 Yokohama Rubber Co Ltd:The Collection of l-quebrachitol in natural rubber serum
EP0589074B1 (en) 1992-09-22 2001-11-21 Takeo Dr. Takayanagi Carbohydrate complexes for destruction of resistant cancer cells
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
AUPO864097A0 (en) 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
MY139558A (en) * 2003-02-28 2009-10-30 Malaysian Rubber Board A protein
EP2926818A1 (en) 2004-03-26 2015-10-07 La Jolla Pharmaceutical Company Modified pectins, compositions and methods related thereto
MY153171A (en) * 2006-12-21 2015-01-29 Thailand Ct Of Excellence For Life Sciences Skin whitening composition containing extracts derived from natural rubber latex
US8491969B2 (en) * 2008-06-27 2013-07-23 Akzo Nobel N.V. Redispersible polymer powder
CN102516041A (en) * 2011-12-16 2012-06-27 云南省热带作物科学研究所 Method for extracting quebrachitol from natural rubber whey

Also Published As

Publication number Publication date
CN110023342B (en) 2022-01-11
EP3510052A1 (en) 2019-07-17
CN110023342A (en) 2019-07-16
EP3510052A4 (en) 2020-06-17
WO2018044242A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
AU2017296095B2 (en) Multispecific antibodies against CD40 and CD137
WO2016182959A8 (en) Optimized crispr/cas9 systems and methods for gene editing in stem cells
MY197091A (en) Compositions for treating acid-base disorders
MX2019014711A (en) Proton-binding polymers for oral administration.
MX2021013880A (en) Proton-binding polymers for oral administration.
MX2018010508A (en) Improved preparations of adult liver progenitor cells.
WO2013088148A3 (en) Method of treatment employing therapeutic t cell product from mobilised donors
WO2015200828A8 (en) Conjugates for immunotherapy
EA201791518A1 (en) METHODS TO TREAT DISEASES OF THE RETAIL
MX2023002076A (en) Treatment for tumors driven by metabolic dysfunction.
MA40458A (en) Methods of treating cervical cancer
WO2019118793A3 (en) Subject-specific tumor inhibiting cells and the use thereof
MY197240A (en) Method for preparing an extract of hevea latex and composition thereof
MX2019005693A (en) Red blood cell targeted factor viii and method of using the same.
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
CN105189786A8 (en) The FALZ of the target of therapy as treating cancer
WO2012156473A3 (en) A set of micrornas as markers and targets in cancer and immune system related diseases, methods for their application and a kit
WO2017049327A3 (en) In vivo priming of natural killer cells
Dehghan et al. The effect of 8-week low impact aerobic exercise on plasma fibrinogen concentration in old women
JP2019031470A5 (en)
EA201650085A1 (en) METHOD OF TREATMENT OF TUMOR DISEASES AND METHOD OF SELECTIVE INHIBITION OF GROWTH OF TUMOR CELLS WITH THE HELP OF CHINOXALIN-1,4-DIOXIDE DERIVATIVE
WO2014145843A3 (en) Methods for treating cancer
Maleki et al. The expression of P21 in esophageal carcinoma cells was enhanced by combination of 7-geranyloxycoumarin and paclitaxel
MX2014014233A (en) Method for obtaining slim films from wheat proteins used as extended-release systems.
Bölk et al. Impact of the red-vine leaf extract AS195 on nitric oxide bioavailability in diabetes patients and its potential role in the wound healing process